Molecular remissions after non-myeloablative allografting for chronic myelocytic leukemia (CML).

被引：0
|
作者：
McSweeney, P
Niederwieser, D
Shizuru, J
Radich, J
Molina, A
Hegenbart, U
Chauncey, T
Sandmaier, B
Wolff, D
Blume, K
Storb, R
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ Leipzig, Leipzig, Germany
[4] Stanford Univ, Stanford, CA 94305 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3135
引用
收藏
页码：710A / 710A
页数：1
相关论文
共 50 条
  • [41] The role of allogeneic hematopoietic cell transplantation with non-myeloablative conditioning in chronic myeloid leukemia.
    Gurman, G
    Arat, M
    Soydan, E
    Dalva, K
    Ilhan, O
    Uysal, A
    Beksac, M
    BLOOD, 2001, 98 (11) : 375B - 376B
  • [42] Results of a non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia.
    Ruiz-Argüelles, GJ
    Gómez-Almaguer, D
    López-Martínez, B
    Cantú-Rodríguez, OG
    Jaime-Pérez, JC
    González-Llano, O
    Herrera-Garza, JL
    BLOOD, 2002, 100 (11) : 453B - 454B
  • [43] EXPERIENCE ON TREATMENT OF CHRONIC MYELOCYTIC-LEUKEMIA (CML) IN BLASTIC CRISIS
    MANDELLI, F
    AMADORI, S
    ALIMENA, G
    ANNINO, L
    NARDELLI, S
    PAPA, G
    SCANDINAVIAN JOURNAL OF HAEMATOLOGY, 1977, 19 (05): : 496 - 502
  • [44] Engraftment after non-myeloablative transplants; still an issue
    Schouten, HC
    Jansen, M
    Bos, G
    Jansen, RLH
    Lalisang, RI
    Wagstaff, J
    BONE MARROW TRANSPLANTATION, 2001, 27 : S292 - S292
  • [45] Mismatched BMT after non-myeloablative conditioning.
    Isola, LM
    Scigliano, E
    Rosina, O
    Najfeld, V
    Fruchtman, SM
    BLOOD, 2000, 96 (11) : 300B - 301B
  • [46] Factors affecting thymopoiesis after non-myeloablative conditioning
    Castermans, E.
    Hannon, M.
    Cheynier, R.
    Willems, E.
    Gothot, A.
    Geenen, V.
    Beguin, Y.
    Baron, F.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S280 - S280
  • [47] Impact of rituximab on immunomodulation and survival after non-myeloablative allogeneic stem cell transplantation (NST) for chronic lymphocytic leukemia (CLL).
    Khouri, IF
    Lee, MS
    Saliba, RM
    Korbling, M
    McMannis, JD
    Keating, MJ
    Champlin, RE
    BLOOD, 2003, 102 (11) : 727A - 727A
  • [48] Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma
    Bruno, Benedetto
    Storer, Barry
    Patriarca, Francesca
    Rotta, Marcello
    Sorasio, Roberto
    Allione, Bernardino
    Carnevale-Schianca, Fabrizio
    Giaccone, Luisa
    Festuccia, Moreno
    Brunello, Lucia
    Omede, Paola
    Ferrando, Federica
    Bringlien, Sara
    Aglietta, Massimo
    Levis, Alessandro
    Mordini, Nicola
    Gallamini, Andrea
    Palumbo, Antonio
    Fanin, Renato
    Storb, Rainer
    Gooley, Ted
    Boccadoro, Mario
    BLOOD, 2010, 116 (21) : 233 - 233
  • [49] Low-dose TBI-based non-myeloablative allografting in newly diagnosed multiple myeloma
    Bruno, B
    Patriarca, F
    Rotta, M
    Maloney, D
    Mordini, N
    Casini, M
    Rambaldi, A
    Carnevale-Schianca, F
    Allione, B
    Soligo, D
    Bavaro, P
    De Fabritiis, P
    Giaccone, L
    Aitoro, G
    Corradini, P
    Busca, A
    Fanin, R
    Gallamini, A
    Coser, P
    Levis, A
    Aglietta, M
    Pogliani, E
    Falda, M
    Massaia, M
    Palumbo, A
    Sandmaier, B
    Storb, R
    Boccadoro, M
    BONE MARROW TRANSPLANTATION, 2004, 33 : S9 - S10
  • [50] Induction of molecular remissions in chronic myelogenous leukemia (CML) with nonmyeloablative HLA-identical sibling allografts.
    Sandmaier, BM
    Niederwieser, D
    McSweeney, PA
    Shizuru, J
    Maloney, DG
    Radich, J
    Chauncey, T
    Deininger, M
    Blume, KG
    Storb, R
    BLOOD, 2000, 96 (11) : 201A - 201A
12345